Artivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide.
$20.64+2.13%
报价 2026-11-09
市值
$1.01B
EV
$1.36B
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -56.7%
$20.10$47.63
筛选结果
pipeline · 2026-11-09Filter✗ 高增长✗ Cheap✗ GARP
does not hit growth, cheap, or GARP pool
爆发潜力
2026-11-09未命中✗ 收入线✗ EPS 线
| 财年 | 收入倍数 | EPS | PE |
|---|---|---|---|
| FY+22027-12 | 1.1x | 0.19 → 0.29（1.5x） | 71.5 |
| FY+32028-12 | 1.3x | 0.19 → 0.46（2.4x） | 44.6 |
毛利率 62% · TTM 收入 $482M · 基数 EPS 0.19（调整后）
一次性亏损已剔除
电话会信号
辅助标签Q3 20262026-11-05
扩产需求加速供不应求
指引 维持
信心 4
分析师 3
“NEXUS U.S. launch expected January 2027, with meaningful revenue contribution beginning then and building through the year.”
原文引用（3）
- 扩产：our focus will remain on expanding manufacturing capacity and building inventory
- 需求加速：the number of U.S. implants increased in the second quarter, which we believe reflects the impact of our recent PMA approval
- 供不应求：they've been supply constrained. We've invested, as we've talked on previous calls, significantly in our Austin manufacturing facility
蓝色标签在暴涨研究中略有区分度；悬停查看口径。
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| AORTArtivion, Inc. | $1.01B | +2.1% | +11.1% | 61.4% | – | 32.4x | – | |
| COGTCogent Biosciences, Inc. | $5.82B | +6.0% | +300.0% | 0% | – | – | – | |
| LFSTLifeStance Health Group, Inc. | $5.58B | +6.0% | +20.3% | 35.4% | 76.8x | 37.4x | 31.1x | GARP |
| ITGRInteger Holdings Corporation | $4.3B | -0.1% | -1.5% | 24.3% | 34.2x | 18.0x | 38.2x | |
| LQDALiquidia Corporation | $4.28B | +7.8% | +365.9% | 92.5% | 30.2x | 23.0x | 70.1x | |
| ARDTArdent Health Partners, LLC | $2.53B | +3.9% | +1.7% | 15.9% | 17.3x | 8.3x | 12.2x | |
| ADUSAddus HomeCare Corporation | $2.29B | -1.5% | +7.2% | 32.2% | 20.3x | 12.9x | 14.1x | |
| BKDBrookdale Senior Living Inc. | $2.22B | +3.3% | -9.0% | 28.7% | – | 7.6x | 153.0x | |
| INSPInspire Medical Systems, Inc. | $1.86B | +0.5% | -5.9% | 85.5% | 14.8x | 22.8x | 17.1x | |
| 同行中位数 | – | – | +4.4% | 30.4% | 25.3x | 18.0x | 31.1x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
| Metric | 2026-09-30 Q3 2026 | 2026-06-30 Q2 2026 | 2026-03-31 Q1 2026 | 2025-12-31 Q4 2025 | 2025-09-30 Q3 2025 | 2025-06-30 Q2 2025 | 2025-03-31 Q1 2025 | 2024-12-31 Q4 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $123.8M | $125.8M | $116.3M | $116M | $113.4M | $113M | $99M | $97.3M |
| Gross Margin | 61.4% | 64% | 61.5% | 60.1% | 65.6% | 64.7% | 64.2% | 63.2% |
| Operating Margin | 2.4% | -6.7% | 6.4% | 6.2% | 11.1% | 7.4% | 2.2% | 2.7% |
| Net Income | $-7.9M | $-13.5M | $1.4M | $2.4M | $6.5M | $1.3M | $-505,000 | $-16.5M |
| Diluted EPS | -0.16 | -0.28 | 0.03 | 0.05 | 0.13 | 0.03 | -0.01 | -0.39 |
| Operating Cash Flow | $-4.6M | $-1.3M | $1.2M | $19.6M | $22.3M | $15M | $-17M | $10.1M |